迈威生物：9MW3811注射液临床试验申请获受理

Core Viewpoint - Maiwei Biotech has received the acceptance notice from the National Medical Products Administration for the Phase II clinical trial application of 9MW3811 injection for pathological scars, marking a significant step in its development pipeline [1] Group 1: Product Development - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, developed independently by Maiwei Biotech and holds proprietary intellectual property [1] - Preclinical studies have demonstrated significant efficacy of 9MW3811 in various models, including pulmonary fibrosis, and it shows potential application value in fibrosis-related diseases such as scar hyperplasia and abnormal uterine bleeding [1] - The company plans to initiate the Phase II clinical trial for 9MW3811 targeting pathological scars by the end of 2025, positioning it as one of the first IL-11 targeted drugs to enter clinical stages in this indication area [1]